On January 15, 2015, CTI Capital announced it had successfully raised $134 million in its second venture capital fund. The new fund includes support from Quebec institutional investors, with participation from Teralys Capital and BDC Capital. CTI II will continue to invest in biotherapeutics, medical technologies and healthcare IT and will seek to build companies that will develop assets at the pre-clinical to early clinical phase.
CTI Capital is a Montreal-based private venture capital fund investing in high quality emerging life science companies.
Osler, Hoskin & Harcourt LLP advised CTI Capital with a team consisting of Shahir Guindi, Jeremy Brisset (Corporate) and Chima Ubani (Emerging & High Growth Companies).